The Diagnostic Value of bpMRI in Prostate Cancer: Benefits and Limitations Compared to mpMRI.

IF 3.8 3区医学 Q2 ENGINEERING, BIOMEDICAL Bioengineering Pub Date : 2024-10-09 DOI:10.3390/bioengineering11101006

Roxana Iacob, Diana Manolescu, Emil Robert Stoicescu, Simona Cerbu, Răzvan Bardan, Laura Andreea Ghenciu, Alin Cumpănaș

{"title":"The Diagnostic Value of bpMRI in Prostate Cancer: Benefits and Limitations Compared to mpMRI.","authors":"Roxana Iacob, Diana Manolescu, Emil Robert Stoicescu, Simona Cerbu, Răzvan Bardan, Laura Andreea Ghenciu, Alin Cumpănaș","doi":"10.3390/bioengineering11101006","DOIUrl":null,"url":null,"abstract":"<p><p>Prostate cancer is the second most common cancer in men and a leading cause of death worldwide. Early detection is vital, as it often presents with vague symptoms such as nocturia and poor urinary stream. Diagnostic tools like PSA tests, ultrasound, PET-CT, and mpMRI are essential for prostate cancer management. The PI-RADS system helps assess malignancy risk based on imaging. While mpMRI, which includes T1, T2, DWI, and dynamic contrast-enhanced imaging (DCE), is the standard, bpMRI offers a contrast-free alternative using only T2 and DWI. This reduces costs, acquisition time, and the risk of contrast-related side effects but has limitations in detecting higher-risk PI-RADS 3 and 4 lesions. This study compared bpMRI's diagnostic accuracy to mpMRI, focusing on prostate volume and PI-RADS scoring. Both methods showed strong inter-rater agreement for prostate volume (ICC 0.9963), confirming bpMRI's reliability in this aspect. However, mpMRI detected more complex conditions, such as periprostatic fat infiltration and iliac lymphadenopathy, which bpMRI missed. While bpMRI offers advantages like reduced cost and no contrast use, it is less effective for higher-risk lesions, making mpMRI more comprehensive.</p>","PeriodicalId":8874,"journal":{"name":"Bioengineering","volume":"11 10","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11505328/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioengineering","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3390/bioengineering11101006","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Prostate cancer is the second most common cancer in men and a leading cause of death worldwide. Early detection is vital, as it often presents with vague symptoms such as nocturia and poor urinary stream. Diagnostic tools like PSA tests, ultrasound, PET-CT, and mpMRI are essential for prostate cancer management. The PI-RADS system helps assess malignancy risk based on imaging. While mpMRI, which includes T1, T2, DWI, and dynamic contrast-enhanced imaging (DCE), is the standard, bpMRI offers a contrast-free alternative using only T2 and DWI. This reduces costs, acquisition time, and the risk of contrast-related side effects but has limitations in detecting higher-risk PI-RADS 3 and 4 lesions. This study compared bpMRI's diagnostic accuracy to mpMRI, focusing on prostate volume and PI-RADS scoring. Both methods showed strong inter-rater agreement for prostate volume (ICC 0.9963), confirming bpMRI's reliability in this aspect. However, mpMRI detected more complex conditions, such as periprostatic fat infiltration and iliac lymphadenopathy, which bpMRI missed. While bpMRI offers advantages like reduced cost and no contrast use, it is less effective for higher-risk lesions, making mpMRI more comprehensive.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

前列腺癌 bpMRI 的诊断价值：与 mpMRI 相比的优势和局限。

前列腺癌是男性第二大常见癌症，也是全球男性死亡的主要原因之一。由于前列腺癌通常表现为夜尿、排尿不畅等模糊症状，因此早期发现至关重要。PSA检测、超声波、PET-CT和mpMRI等诊断工具对前列腺癌的治疗至关重要。PI-RADS 系统有助于根据成像评估恶性风险。mpMRI 包括 T1、T2、DWI 和动态对比增强成像 (DCE)，是标准的 mpMRI，而 bpMRI 则是仅使用 T2 和 DWI 的无对比替代方法。这减少了成本、采集时间和造影剂相关副作用的风险，但在检测风险较高的 PI-RADS 3 和 4 病变方面存在局限性。这项研究比较了 bpMRI 和 mpMRI 的诊断准确性，重点是前列腺体积和 PI-RADS 评分。两种方法在前列腺体积方面都显示出很强的评分者间一致性（ICC 0.9963），证实了 bpMRI 在这方面的可靠性。不过，mpMRI 能检测出更复杂的情况，如前列腺周围脂肪浸润和髂淋巴结病，而 bpMRI 却漏检了这些情况。虽然 bpMRI 具有成本低、无需使用造影剂等优点，但对高风险病变的效果较差，因此 mpMRI 更为全面。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Bioengineering Chemical Engineering-Bioengineering

CiteScore

4.00

自引率

8.70%

发文量

661

期刊介绍： Aims Bioengineering (ISSN 2306-5354) provides an advanced forum for the science and technology of bioengineering. It publishes original research papers, comprehensive reviews, communications and case reports. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. All aspects of bioengineering are welcomed from theoretical concepts to education and applications. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. There are, in addition, four key features of this Journal: ● We are introducing a new concept in scientific and technical publications “The Translational Case Report in Bioengineering”. It is a descriptive explanatory analysis of a transformative or translational event. Understanding that the goal of bioengineering scholarship is to advance towards a transformative or clinical solution to an identified transformative/clinical need, the translational case report is used to explore causation in order to find underlying principles that may guide other similar transformative/translational undertakings. ● Manuscripts regarding research proposals and research ideas will be particularly welcomed. ● Electronic files and software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material. ● We also accept manuscripts communicating to a broader audience with regard to research projects financed with public funds. Scope ● Bionics and biological cybernetics: implantology; bio–abio interfaces ● Bioelectronics: wearable electronics; implantable electronics; “more than Moore” electronics; bioelectronics devices ● Bioprocess and biosystems engineering and applications: bioprocess design; biocatalysis; bioseparation and bioreactors; bioinformatics; bioenergy; etc. ● Biomolecular, cellular and tissue engineering and applications: tissue engineering; chromosome engineering; embryo engineering; cellular, molecular and synthetic biology; metabolic engineering; bio-nanotechnology; micro/nano technologies; genetic engineering; transgenic technology ● Biomedical engineering and applications: biomechatronics; biomedical electronics; biomechanics; biomaterials; biomimetics; biomedical diagnostics; biomedical therapy; biomedical devices; sensors and circuits; biomedical imaging and medical information systems; implants and regenerative medicine; neurotechnology; clinical engineering; rehabilitation engineering ● Biochemical engineering and applications: metabolic pathway engineering; modeling and simulation ● Translational bioengineering